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Abstract: The role of intellectual property in the pharmaceutical industry has been controversial for decades. On one hand,
evidence suggests that patents and monopolies on drug sales for
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limited periods are necessary to fund costly R&D required to produce life-saving therapies. On the other, there is concern that patent rights have gone too far in favour of innovation, limiting access
to lower-income populations who cannot afford exorbitant drug
prices. This tension plays out at a grander scale in the international context, as drug prices can vary drastically between countries, as has happened in the COVID-19 pandemic.
In 2017, the United States Supreme Court held in Lexmark that a
patentee’s rights are exhausted after international sale. This decision has immense implications for the U.S. pharmaceutical industry and the affordability of medicines worldwide. Legislators such
as Senator Bernie Sanders have proposed bills in light of the decision to lower American drug prices by permitting importation from
countries like Canada. Though FDA and other regulatory barriers
may still be present, American innovator companies can no longer
sue reimports on the grounds of patent infringement.
However, while the results may be favourable to U.S. consumers,
international impacts remain to be seen. Some suggest that prices
in countries like India could increase to reduce opportunities for
arbitrage. In this article, we suggest methods for branded pharmaceutical companies to address issues arising from Lexmark while
simultaneously providing affordable access—from voluntary licensing to avoid the risk of compulsory licenses and creative forms of
contracting. Finally, we conclude regarding India’s newfound consumer protection laws to note that American pharmaceutical players may not simply be able to lower product standards to prevent
parallel importation back to the US.
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I. INTRODUCTION TO INTERNATIONAL PATENT
EXHAUSTION IN THE PHARMACEUTICAL INDUSTRY

The foundation of patent protection was borne from a desire, per Alexander
Hamilton in his Report on Manufactures, to encourage, “new inventions and
discoveries at home, and of the introduction into the United States of such
as may have been made in other countries; particularly, those which relate to
machinery.”1 This desire drove the formation and development of the patent
system.
However, over time, the patent system has gained detractors due to the negative consequences. For instance, Stephen Hawking has euphemistically said:
“We think we have solved the mystery of creation. Maybe we should patent
the universe and charge everyone royalties for their existence.”2 Hawking
is satirically referencing the push toward a gold rush in the patent world.3 In
other words, Hawking’s commentary highlights the shift in motivations from
the Hamiltonian age to the present, where monetization and prevention are the
main motivators.

A. Patents in the Pharmaceutical Industry and Societal Impacts
In the pharmaceutical industry, in particular, patents often hinder access to
medicine to the developing parts of the world. Such a consequence is perhaps
more acute in the pharmaceutical industry than others, due to the humanitarian
nature of the industry. Patenting can limit access to medicine by contributing
to the increased costs of development, that are then passed to the customer,
while the patent holder also controls the distribution.4

1

2

3
4

Robert P. Merges, ‘The Hamiltonian Origins of the U.S. Patent System, and Why They Matter
Today’ (2019) 104 Iowa L Rev 2559 <https://ilr.law.uiowa.edu/print/volume-104-issue-5/thehamiltonian-origins-of-the-u-s-patent-system-and-why-they-matter-today/> accessed April
2021.
‘An Inventor’s Guide to Understanding Patent Eligibility’ (InQuartik, 15 October 2020)
<https://www.inquartik.com/blog/basic-inventors-guide-understanding-patent-eligibility/>
accessed 5 April 2021.
ibid.
Michelle Chen, ‘Patents Against People: How Drug Companies Price Patients out of Survival’
(Dissent Magazine, 9 December 2013) <https://www.dissentmagazine.org/article/patentsagainst-people-how-drug-companies-price-patients-out-of-survival> accessed 6 April 2021.
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Further, commentators have reasoned that not only do pharmaceutical patents promote a business model incentivizing high price points but that patents
also prevent further innovation from occurring.5 This is primarily because
pharmaceutical companies have been incentivized, at least in part by the patent system, to only make drugs that are high market potential.6 Further, critics contend that most innovation comes from academic centers and research
institutions, while much of pharmaceutical spending is on marketing and
advertising.7
While intellectual property protection is important in the pharmaceutical
sector given the high costs of R&D, with widely cited studies showing that the
median cost for bringing a drug to market is $985 million,8 abuses such as the
development of copycat drugs to extend patent life and abnormally high profit
margins remain as top concerns for healthcare consumers.9 The monetary and
predatory consequences, therefore, of the patent system cannot be ignored in
the pharmaceutical industry.
Perhaps the finest example of the confrontation between pushing innovation through patent law and its consequences is the situation in South Africa
in the mid to late 1990s. At the time, South Africa was experiencing one of
the fastest expanding HIV/AIDS epidemics in the world.10 The patients, due
to high prices, had no or very limited access to lifesaving antiretroviral therapy (“ART”).11 However, the ART medications were being sold at lower prices
abroad, and thus, Nelson Mandela’s South African Government passed the
South African Medicines and Related Substances Control Act Amendments.12
Of particular interest to the pharmaceutical industry and the patent industry,
was Section 15(c), which indicated that the South African government believe
5

6
7

8

9
10

11
12

‘Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?’ (The Wall Street
Journal, 23 January 2012) <https://www.wsj.com/articles/SB10001424052970204542404577156
993191655000> accessed 6 April 2021.
ibid.
Michele Boldrin and David Levine, ‘The Pharmaceutical Industry’ in Michele Boldrin and
David K. Levine (eds), Against Intellectual Monopoly (Cambridge University Press 2010).
Olivier Wouters, Martin McKee and Jeroen Luyten, ‘Estimated Research and Development
Investment Needed to Bring a New Medicine to Market, 2009-2018’ (2020) 323 JAMA
844-853.
Chen (n 4).
Burcu Kilic and Peter Maybarduk, ‘The Lexmark Litigation: Why Does Big Pharma Care So
Much About Ink Cartridges?’ (Intellectual Property Watch, 17 September 2015) <https://www.
ip-watch.org/2015/09/17/the-lexmark-litigation-why-does-big-pharma-care-so-much-about-inkcartridges/> accessed 8 April 2021.
ibid.
Debora Halbert, ‘Moralized Discourses: South Africa’s Intellectual Property Fight for Access
to AIDS Drugs’ (2002) 1 Seattle Journal for Social Justice 257 <https://digitalcommons.law.
seattleu.edu/cgi/viewcontent.cgi?article=1231&context=sjsj> accessed 8 April 2021.
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it was permitted to engage in compulsory licensing and parallel importation of
drugs to provide access at prices affordable to South Africans.13
At the time, the South African government believed it was acting in accordance with the Trade-Related Aspect of Intellectual Property Right (“TRIPS”)
agreement, which allowed each member of the World Trade Organization
(“WTO”) to design its regime concerning exhausting of patents.14 In other
words, this freedom, allowed countries to shop for the lowest price of a drug
and import that drug at the lower price.15 While the South African legislation
took a human rights-based approach, it was not long before multinational –
mainly, American – pharmaceutical companies began admonishing the South
African legislation. Namely, the companies argued that the legislation was a
violation of TRIPS, which resulted in an international dispute that was framed
as a battle between commercial interests and human rights.16
TRIPS, in general terms, established minimum standards for the availability, scope, and use of seven forms of intellectual property: copyrights, trademarks, geographical indications, industrial designs, patents, layout designs
for integrated circuits, and undisclosed information (trade secrets).17 It spells
out permissible limitations and exceptions in order to balance the interests of
intellectual property with interests in other areas, such as public health and
economic development.18 Notably, the 2001 Doha Declaration on the TRIPS
agreement responded to concerns about access to affordable medicines in
developing countries, allowing the use of compulsory licenses on a case-bycase basis.19 The agreement was driven by worries about obstacles to access
care for diseases of public health importance, including HIV, tuberculosis, and
malaria.20

13
14

15
16

17

18
19

20

ibid 269.
Burcu Kilic and Peter Maybarduk, ‘The Lexmark Litigation: Why Does Big Pharma Care So
Much About Ink Cartridges?’ (Intellectual Property Watch, 17 September 2015) <https://www.
ip-watch.org/2015/09/17/the-lexmark-litigation-why-does-big-pharma-care-so-much-about-inkcartridges/> accessed 8 April 2021.
ibid.
Debora Halbert, ‘Moralized Discourses: South Africa’s Intellectual Property Fight for Access
to AIDS Drugs’ (2002) 1 Seattle Journal for Social Justice 257 <https://digitalcommons.law.
seattleu.edu/cgi/viewcontent.cgi?article=1231&context=sjsj> accessed 14 April 2021.
‘Trade Related Aspects of IP Rights’ (United States Patent and Trademark Office - An
Agency of the Department of Commerce, 1 November 2019) <https://www.uspto.gov/ip-policy/
trade-related-aspects-ip-rights> accessed 6 April 2021.
ibid.
World Health Organization, ‘The Doha Declaration on the TRIPS Agreement and Public
Health’ <https://www.who.int/medicines/areas/policy/doha_declaration/en/> accessed 14 April
2021.
ibid.
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In 2001, the pharmaceutical companies dropped all their litigation, primarily because it became a public relations disaster for them.21 The events from
the 1990s to the early 2000s highlight the conflict between the commercial
interests and moral responsibilities that conflict in the pharmaceutical world, at
least in part due to patent rights.

B. Patent Exhaustion
After the events of the 1990s and early 2000s, it was clear that the patent
exhaustion doctrine needed further clarification as the world became increasingly intermingled. Further clarity was provided when the United States
Supreme Court made a decision related to patent exhaustion in Impression
Products, Inc. v Lexmark International, Inc., No. 15-1189 (U.S. 30th May
2017).
Lexmark answered two issues: (1) whether a patentee can sue, under patent
infringement, a downstream market participant who violates the restrictions on
the right to reuse or resell that were imparted during the original sale; and (2)
whether patent exhaustion applies irrespective of where the product was sold.22
The U.S. Supreme Court held, unanimously, that patent exhaustion applies
regardless of post-sale restrictions and held 7–1 (with Ginsberg J. dissenting)
that patent exhaustion applies regardless of the country where the product is
sold.23
The Lexmark decision provided a clear break where a patentee’s rights
are terminated. The decision aligned with public sentiment in that patent law
should not be invoked to restrain downstream use and sale of that item.24 In
the pharmaceutical industry, the implications continue to be felt. However,
some implications are clear: pharmaceutical companies may want to recoup
investments in their first sale because they are not able to control the sale of
their patented drugs through post-sale restrictions or prevent competition due
to differential pricing models used abroad. As such, the Lexmark ruling, while
mostly in line with the sentiment created in the 1990s, may financially burden
21

22

23
24

Burcu Kilic and Peter Maybarduk, ‘The Lexmark Litigation: Why Does Big Pharma Care So
Much About Ink Cartridges?’ (Intellectual Property Watch, 17 September 2015) <https://www.
ip-watch.org/2015/09/17/the-lexmark-litigation-why-does-big-pharma-care-so-much-about-inkcartridges/> accessed 8 April 2021.
Impression Products Inc v Lexmark International Inc No 15-1189 (US 30 May 2017) <https://
www.supremecourt.gov/opinions/16pdf/15-1189_ebfj.pdf> accessed 8 April 2021.
ibid.
Dan Bagatell, Dana Hayter and Christopher Stanton, ‘First Impressions: New Strategies in
the New Era of Patent Exhaustion After Impression Products v. Lexmark International’ (JD
Supra, 14 June 2017) <https://www.jdsupra.com/legalnews/first-impressions-new-strategies-inthe-63488/> accessed 6 April 2021.
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pharmaceutical companies. While the Supreme Court has made it near impossible for the pharmaceutical industry to return to the economics of a pre-HIV
era, legislators are also doing their part to close the possibility of return even
further.

C. Food and Drug Administration
In addition to the patent exhaustion doctrine, the Food and Drug
Administration (“FDA”) has sections that prohibit and allow certain international movement of drugs. First, under Section 505 of the Federal Food, Drug,
and Cosmetic Act (“FDCA”), any new drug that is not subject to an approved
new drug application (“NDA”) or abbreviated NDA (“ANDA”) cannot be introduced into interstate commerce.25 This section is obvious to most consumers; a
drug needs to be approved before being imported. Second, per Section 801(d)
of the FDCA – of Title 21 U.S.C. § 381(d) – it is illegal to import the foreign
version of an FDA-approved drug.26 The reasoning of this section is because
the FDA approves a drug based on specific factors such as the label and where
it was manufactured.27
The FDA’s ordinances, in some ways, seem to contradict the sentiment
behind Lexmark. Namely, Lexmark permits exhaustion after sale abroad and
thereby allows a product that is sold at a cheaper price abroad, to be resold in
America at a cheaper price. The FDA, conversely, does not permit foreign versions of FDA-approved drugs into the U.S. This conflict is part of the reason
that Congress feels the need to rethink this issue.
II. PROPOSED LEGISLATION IN THE US

With the above context in mind, and with no intention to be advocating any
political position, there are currently three bills that Vermont Senator Bernie
Sanders (with others) has proposed to the Senate. Senator Sanders says that the
bills are meant to, “drastically reduce prescription drug prices in the United
States. The time is now to stand up to the pharmaceutical industry and say
enough is enough. The greed of drug companies is out of control and the cost
is human lives.”28
25

26
27
28

Dennis Crouch, ‘Demystifying Drug Importation after Impression v. Lexmark’ (Patently-O,
6 June 2017) <https://patentlyo.com/patent/2017/06/demystifying-importation-impression.html>
accessed 6 April 2021.
ibid.
Crouch (n 25).
‘NEWS: Sanders, Khanna, Doggett, Welch, Bush Introduce Sweeping Legislation to Lower
Drug Prices’ (Senator Bernie Sanders, 23 March 2021) <https://www.sanders.senate.gov/
press-releases/news-sanders-khanna-doggett-welch-bush-introduce-sweeping-legislation-tolower-drug-prices/> accessed 6 April 2021.

102

INTERNATIONAL JOURNAL ON CONSUMER LAW AND PRACTICE

VOL. 9

A. The Prescription Drug Price Relief Act
The bill requires the Department of Health and Human Services (“HHS”) to
review at least annually all brand-name drugs for excessive pricing and assess
prices upon petition.29 If any drugs are found to be excessively (defined below)
priced, HHS must: (1) void any government-granted exclusivity; (2) issue
open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products.30
HHS must also create a public database with its determinations for each drug.31
Under this bill, the price of a drug is considered excessive if it is above the
median prices of the drug in Canada, the United Kingdom (U.K.), Germany,
France, and Japan.32

B. The Medicare Drug Price Negotiation Act
This bill makes a series of changes relating to the prices of prescription
drugs under the Medicare prescription drug benefit and Medicare Advantage
(“MA”) prescription drug plans (“PDPs”).33 Under the status quo, the Centers
for Medicare & Medicaid Services (“CMS”) may not negotiate the prices of
covered drugs or establish a formulary. This bill repeals these restrictions and
requires the CMS to: (1) negotiate the prices of covered drugs; and (2) either
establish a formulary for covered drugs or require changes to PDP formularies
that take into account CMS negotiations.34 If the CMS is unable to negotiate
a reasonable price for a drug, the price must be the lowest of three specified
options (eg, the average price in other countries).35
Such an approach would be modelled off the UK’s National Institute for
Health and Care Excellence (“NICE”). NICE makes economic evaluations of
healthcare technologies by measuring cost-effectiveness of certain drugs relative to alternatives.36 Based on these determinations, the National Health
Service (“NHS”) negotiates with pharmaceutical companies and makes purchasing decisions.37 Since the NHS acts as a centralized gateway for drugs
entering the U.K., it has the bargaining power to lower prices and increase the
29
30
31
32
33
34
35
36

37

Prescription Drug Price Relief Act 2021.
ibid.
ibid.
ibid.
The Medicare Drug Price Negotiation Act 2021.
ibid.
ibid.
Christopher McCabe, Karl Claxton, and Anthony Culyer, ‘The NICE Cost-Effectiveness
Threshold: What it is and What that Means’ (2008) 26(9) Pharmacoeconomics 733.
House of Parliament, ‘Drug Pricing’ https://www.parliament.uk/globalassets/documents/post/
postpn_364_Drug_Pricing.pdf> accessed 14 April 2021.
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accessibility of care to patients. Sanders’s Medicare Drug Price Negotiation bill
would allow CMS to similarly negotiate for lower drug prices as a centralized
body, overcoming the existing fragmentation in the US healthcare industry that
contributes to higher-than-average medicine prices.38
Additionally, Senator Sanders’s plan requires drug manufacturers to issue
rebates to the CMS for drugs dispensed to eligible low-income individuals.39
Subject to civil monetary penalties, a Medicare or MA PDP sponsor must
report, both to drug manufacturers and the CMS, specified information related
to the determination and payment of such rebates.40

C. The Affordable and Safe Prescription Drug Importation Act
This bill addresses the importation of qualifying drugs that are manufactured at FDA-inspected facilities in Canada.41 The bill requires the FDA to
promulgate regulations within 180 days permitting wholesalers, pharmacies,
and individuals to import certain prescription drugs from Canada.42 After two
years, the FDA may permit the importation of prescription drugs from other
countries.43

D. Constitutional Questions
In practice, these bills would allow government entities (eg, HHS), if the
companies do not lower drug prices, to expedite the approval of generics and/
or control pricing, regardless of any patents or government-granted exclusivities that are in place. The question arises, then, whether patents grant complete freedom to do as a patentee would like or whether a patent grants limited
freedom that can be curtailed based on perceived morally questionable actions.
Perhaps, the broader question then would be whether the proposed legislation
constitutes a taking, per the United States Constitution.
The Takings Clause of the Fifth Amendment of the U.S. Constitution
reads: “Nor shall private property be taken for public use, without just
38

39
40
41

42
43

Allie Nawrat, ‘Comparing the US’s Ten Most Expensive Drugs with Prices in the UK’
(Pharmaceutical Technology, 27 January 2020) <https://www.pharmaceutical-technology.com/
features/us-most-expensive-drugs-uk-prices/> accessed 14 April 2021.
The Medicare Drug Price Negotiation Act 2021.
ibid.
Summary of the Affordable and Safe Prescription Drug Importation Act 2019 <https://www.
sanders.senate.gov/wp-content/uploads/Summary-The-Affordable-and-Safe-Prescription-DrugImportation-Act.pdf> accessed 14 April 2021, wherein it is noted: ‘The bill would not permit
… until there is a material change in circumstances.’
ibid.
ibid.
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compensation.”44 This Clause was intended to endorse the principle that the
government should not be able to place burdens on property owners, without
just compensation for causing that burden.45 The Clause has been interpreted
over the years to mean that, at the very least, when the government outright
confiscated property, just compensation should be paid to the owner.46 With
regards to what constitutes property under the Fifth Amendment, it is generally agreed that all forms of private property, animals, corporate stock, leases,
mortgages, and others qualify.47 Intangible property, such as intellectual property rights, including patents, copyrights, trademarks, and trade secrets have
also been accepted as belonging in this category.48 In fact, the Supreme Court
has for more than 100 years recognized that patents are private property (See
United States v Am. Bell Tell Co).49
Further to determine whether patents are property under the Fifth
Amendment, the natural next question is what is just compensation. Again, it
has been widely accepted that just compensation is determined based on the
fair market value of the property.50 In the case of a patent, the fair market
value can be determined, for example, based on royalties that are paid for similar technology (eg, ART unit) patents during their lifetimes.
Patents, therefore, are considered property under the Fifth Amendment
and have viable ways to determine just compensation. Why, then, does
Senator Bernie Sanders believe the proposed legislation is not a violation of
the Constitution? It may be because of the increasing grey area in which governments are allowed to not compensate private property owners, in what is
known as a regulatory taking derived from the state’s police power to secure
the general welfare in areas of health and safety.
For example, the government is not required to compensate private property owners when it requires them to take reasonable steps to avoid pollution
or other releases that harm either public or private property in land, air, and
water.51 Further, the government can also impose fines and court orders, with44

45
46
47
48
49

50
51

Richard A. Epstein and Eduardo M. Peñalver, ‘The Fifth Amendment Takings Clause’ (The
National Constitution Center) <https://constitutioncenter.org/interactive-constitution/interpretation/amendment-v/clauses/634> accessed 7 April 2021.
ibid.
Epstein and Peñalver (n 44).
Epstein and Peñalver (n 44).
Epstein and Peñalver (n 44).
Steve Brachmann and Gene Quinn, ‘Patents as Property Rights: What Will It Take to Restore
Sanity to the Narrative Surrounding US Patents?’ (IPWatchdog, 10 May 2017) <https://www.
ipwatchdog.com/2017/05/10/patents-property-rights/id=83074/> accessed 6 April 2021.
Epstein and Peñalver (n 44).
Epstein and Peñalver (n 44).
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out a duty to compensate, to force a private property owner to stop harmful
activities.52 By expanding the grey area in which the state can regulate harms
in the name of the public good, the government has been able to burden the
individual property owner without triggering just compensation.
Due to expanding gray areas, it is not far-fetched to believe that legislation
such as the ones discussed above, may not trigger just compensation. Namely,
if taking for prevention of “harmful activities” such as pollution is permitted
without just compensation, it may not be a huge leap to consider high drug
prices in a similar category. High drug prices do cause harmful consequences
such as decreased access to drugs, which in the most literal sense, harm lives.
In a recent Supreme Court case, Oil States Energy Services LLC v Greene’s
Energy Group LLC, the Court adjudicated, among other things, whether inter
partes review (“IPR”) violates the Constitution by terminating private property rights through a non-Article-III forum without a jury.53 One of the pillars
of this issue is whether a patent is private property. To which, the Court said
that three decisions—United States v American Bell Telephone, McCormick
Harvesting Machine Co v Aultman, and Brown v Duchesne—recognize patent
rights as the “private property of the patentee.”54 The Court decided that IPRs
are constitutional because an IPR is a “second look at an earlier … grant,” and
it involves the same interests as the earlier grant.55 The fact that IPRs occur
after the grant does not make a difference.
Further, the Court classified a patent as a “public franchise” because the
grant of a patent falls with the public-rights doctrine.56 In other words, because
granting a patent involves a matter between the government and others and
because granting a patent is a constitutional function carried out by the executive and legislative branches, it is considered a public franchise.57 The Court
used an example of a bridge to further illustrate the analogy.58 A bridge, after
it is built, can be subject to certain authority by the government, such as tolling.59 Such an authority is permitted under the public-rights doctrine.60
52
53

54
55
56
57
58

59
60

Epstein and Peñalver (n 44).
Oil States Energy Services LLC v Greene’s Energy Group LLC 2018 SCC OnLine US SC 24
: 200 L Ed 2d 671 584 US (2018) (U.S. 27 November 2017) <https://www.supremecourt.gov/
opinions/17pdf/16-712_87ad.pdf> accessed 6 April 2021.
ibid.
ibid.
ibid.
ibid.
‘Oil States Energy Services v. Greene’s Energy Group’ (Banner Witcoff ) <https://bannerwitcoff.com/issue/oil-states-energy-services-v-greenes-energy-group/> accessed 6 April 2021.
ibid.
ibid.
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Although the decision in Oil States Energy Services seems to further bolster that patent are private property under the Constitution and in particular,
the Takings Clause, further inspection indicates otherwise. Namely, the Court
recognizes that patents are property but endorses the caveat that patents are
considered public franchises. In doing so, the Court has left open the door for
government intrusions. Further, the Court made it clear that an IPR is a second
look at an earlier grant of a patent. By making this clear, the Court allows a
non-Art III court to void a previously granted patent. The basis for doing so is
in patent law; however, the principle of voiding a granted application is getting
more prevalent.
This decision, in parallel with recent trends regarding the Takings Clause
and public sentiment towards pharmaceutical patents, indicates that the grey
area in which government can take without triggering just compensation is
growing. Senator Sanders may have an uphill battle if his legislation is litigated
under a Takings Clause cause of action. However, it seems that the pharmaceutical industry may also have a similar challenge in this situation. History
is against the pharmaceutical companies and another public relations disaster
such as the one in the late 1990s is an ill-advised path.

E. Legitimacy of the Legislation
As it stands, patents are private property under the Takings Clause. Senator
Sanders’ legislation, at least The Prescription Drug Price Relief Act, may be a
violation of the Takings Clause. Given the unambiguous language – the HHS
must void any government-granted exclusivity – a taking is likely to result if
this legislation is passed. And, as it stands, the government would need to pay
just compensation.
However, a public health emergency such as the lack of access to medicine
and price gouging in America may be considered a harmful act that does not
trigger just compensation. Seemingly, the legislation has laid the foundation for
making this argument because of the numerous statistics that are cited as justification. For example, Americans have seen the price of drugs skyrocket as
much as 5,000% overnight and in midst of the COVID-19 pandemic, pharmaceutical companies raised prices on over 860 drugs in 2020.61 Moreover, nearly
1 in 4 adults in the U.S. say it’s difficult to afford their medicines and three in
ten adults did not take their prescribed medicine due to the costs.62
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It remains to be seen whether the proposed legislation will become law.
Irrespective of the legislation, it is clear that the pharmaceutical industry and
how they use their patents are under attack.
III. POTENTIAL IMPACTS OF LEXMARK ON
AFFORDABLE MEDICINES IN INDIA

Prior to Lexmark, pharmaceutical companies were able to block their own
FDA-approved drugs sold in foreign jurisdictions like India (typically at
a lower price) from being resold in the U.S.. Notwithstanding the aforementioned FDA import restrictions on foreign versions of FDA-approved drugs,
pharmaceutical players were able to engage in a double-dipping “sell and sue”
strategy. Now, given international patent exhaustion due to Lexmark, pharmaceutical companies are no longer able to restrict reimports through patent
infringement suits. To avoid blurring the line between highly-priced domestic
drugs and cheaper versions of the same drug abroad, pharmaceutical companies will need to resort to novel pricing and licensing approaches.

A. Impact of Lexmark on Increasing Branded Drug Prices in India
Some experts contend that while Lexmark could have consumer-friendly
effects in the U.S., as demonstrated by the various Bernie Sanders proposals,
an unintended consequence could be higher prices abroad.63 Namely, given that
Lexmark prevents pharmaceutical players from prohibiting the resale of goods
in the U.S. on patent infringement grounds, the cost of drugs will likely be
increased in foreign jurisdictions to limit the opportunities for arbitrage. Thus,
while overall welfare for Americans may increase, relative welfare for those in
India may be reduced.64
However, given the availability of mechanisms like compulsory licensing
as allowed by the Doha Declaration to the TRIPS agreement, pharmaceutical
companies must be cautious to not increase prices so much as to trigger patent circumvention entirely. Thereby, given these constraints, the burdens of
Lexmark will likely fall primarily on the pharmaceutical industry. In a universe wherein the branded pharmaceutical industry is overcharging relative to
R&D spend (given significant advertising expenses and frequent licensing from
academic/governmental institutions at a low cost), this should not greatly affect
innovation, and the companies could just internalize the costs.
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Further, if the prior narratives around me-too drugs and the development
of solely high market-potential drugs – as mentioned above – are true, consumers should have limited concern. But in another universe with slim margins and exorbitant R&D costs, as portrayed by Big Pharma, the changes due
to Lexmark could result in reduced incentives to innovate. Thus, while domestic pricing may be lowered, the “costs” of fewer lifesaving treatments could be
borne worldwide. Nonetheless, it is possible that the U.S. and countries like
India may see price decreases and increases, respectively, so as to limit arbitrage opportunities.
Namely, Lexmark encourages innovator pharmaceuticals to recover as much
profit from the first sale, as downstream control over pricing and royalties has
now disappeared. But given the possibility of the Indian government issuing
a compulsory license – as was done against Bayer in favour of Indian generic
company Natco for the anticancer drug Sorafenib/Nexavar – pharmaceutical
companies are likely wary of this approach.65 In the case, Bayer Corporation
v Union of India, the Indian Intellectual Property Appellate Board (“IPAB”)
upheld the Controller’s decision to grant Natco a non-exclusive license on the
grounds of lacking affordability and resulting limited access.66
Bayer was charging almost 10x the price compared to generic company
CIPLA for the same drug (INR 2,80,000 v INR 28,000).67 The compulsory
license was legally justified with reference to Section 84(1) of the Indian Patent
Act of 1970 (amended in 2005), which is consistent with TRIPS in permitting
a compulsory license when the patented invention “is not available to the public at a reasonably affordable price.”68 While IPAB ultimately mandated that a
7% royalty be paid to Bayer, this minimal allowance and a severely depressed
price point was effectively a complete loss for Bayer in the Indian market.
Though India has been stereotyped as being lenient in granting compulsory licenses, a number of other countries – namely Brazil, Thailand, and various African nations – have invoked this provision more frequently.69 To note,
compulsory licensing is more likely for small molecule treatments with limited manufacturing complexity that local generic companies can easily replicate (and less likely for complicated large molecules). Regardless, the threat of
65
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a possible compulsory license in India will ultimately curb any dramatic price
increase by U.S. pharmacos in India.
Furthermore, in cases of direct sales from U.S. manufacturers to Indian
consumers, there is a greater fear of reimportation to the U.S.. Since the product is of course FDA-approved and was also manufactured within the U.S.,
neither Sections 505 nor 801 of the FDCA would prevent reimportation. Thus,
there is a tension between charging high prices abroad to avoid the risks of
reimportation/arbitrage while not increasing prices so much as to increase the
chance of a compulsory license. But there is one way out of this dilemma: voluntary licensing.

B. Voluntary Licensing between American Innovator Companies and
Indian Generics
One now-proven, effective strategy that innovator pharmaceutical companies
can take to simultaneously avoid the risks of patent exhaustion and compulsory licensing is voluntary licensing. For example, Gilead experimented and
pioneered this approach with its one-pill-a-day regimen HIV therapies in more
than one hundred countries by voluntarily licensing its innovation with reputable pharmaceutical companies in India, including with the Medicines Patent
Pool. In 2014, just months after the U.S. FDA approved Sovaldi as an effective
treatment/cure for Hepatitis C, Gilead built on its earlier successful HIV therapy Voluntary Licensing experience with a focus on increasing access to care
for hepatitis in developing countries, including in India.70
Gilead issued Voluntary Licenses to 11 Indian generic companies, notably
Aurobindo, Mylan, Hetero, Cadila, Cipla, Ranbaxy (Sun), Strides, NATCO,
Ferozsons, Laurus and Biocon to manufacture the product and distribute finished product to ultimately 105 developing countries, in addition to India.
Moreover, this Voluntary License also included therapies that had not yet been
cleared by the FDA such as the pan-genotypic Epclusa which treats multiple
genotypes of HCV, with an effective cure rate of >95%.
Not only does this Voluntary Licensing approach render moot the need for
any country to issue a compulsory license, as the drugs distributed by the
generic companies en masse for the Indian population and for the 105 other
markets included in the Voluntary License, but the cost of the therapy will also
be far less expensive than the equivalent product sold by Gilead and offers the
70
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added bonus of building indigenous technical capability among the cohort of
Voluntary Licensees in that a full technical package is provided by Gilead as
part of the Voluntary License.
This allows the local Voluntary Licensees the ability to deliver at scale
the highest quality therapies to a maximum number of patients at the lowest
possible cost. As part of the Voluntary License, the pharmaceutical innovator
recoups some nominal royalty payments from the Voluntary Licensees, which
in the case of Gilead is reinvested back into its patient access program, with
the end-goal of reaching a maximum number of patients in need of these treatment therapies. The result is that the drug price is significantly reduced, owing
to the specific innovativeness of the Licensee and their manufacturing prowess,
and the ability of the Licensees to scale. Further, the Indian Licensees enjoy
logistical access to many of these far-away markets, enabling them to compete
with one another in these markets, which further drives down pricing.
The result is that the beneficiary is the patient, the end-consumer, while
the Licensees also benefit given the massive population offered in the License
territories, providing the Indian generic companies a revenue stream that is
certainly more favourable than what would be derived by a simple compulsory license (ie, through sheer volume). Further, some studies have shown that
voluntary licensing is preferable to foreign countries relative to a compulsory
license as it enables cooperation in technology transfer, which is especially
important in cases where manufacturing is particularly complex and there is an
emergency, like for the COVID-19 therapies and vaccines.71
Former Gilead Sciences’ CEO, John C. Martin, who helped pioneer the
Voluntary Licensing model for these life-saving therapies, believed that with
such innovation comes a serious responsibility. To a 2019 graduating class of
India Institute of Management Ahmedabad students, Dr. Martin said: “Finding
an effective treatment or a cure for a deadly virus as devastating as Hepatitis
C comes around in science - at best - once every 30 years. When you find a
cure for a deadly disease, you should have only one focus: getting that cure or
treatment to the patients who need it most. Voluntary Licensing is an enabler
of patient access.”
When challenged by a curious student from this same audience, asking
‘Then how does your company recoup costs and make a profit if you give away
licenses and markets for half the world’s countries for your most prized products?’ John Martin replied, “You worry about lives and not money if you are a
71
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serious scientist. You will make your money another day, by inventing another
drug.” For the late John C. Martin, science and patients always came first.
Gilead Sciences’ pioneering Voluntary License model is now a proven concept. Case-in-point: Gilead’s licensing of its HIV therapies presently reaches
and treats as many as 20 million patients each day, allowing these HIVinfected individuals to live a normal life. For its Hepatitis therapies, Gilead’s
Voluntary Licensees have reached and have cured as many as 1 million
patients in India. And with 9 Voluntary Licenses (7 in India, 1 in Pakistan,
and 1 in Egypt), Gilead’s remdesivir is available on the front lines in the fight
against COVID-19, in 127 countries, including India. Namely, the Voluntary
Licensees are Hetero, Mylan, Jubilant, Cipla, Biocon, Dr. Reddy’s Labs,
Cadila, Ferozsons and Eva Pharma.
Regarding exhaustion, it is unclear whether such a voluntary licensing
agreement alone would qualify under the Lexmark regime. More specifically,
exhaustion applies only to the “initial authorized sale of a patented item.”72
The question remains, does such a license really count as a sale? Regardless,
even if we assume that the product in question is FDA-approved, but it is manufactured at a generic facility not approved by the FDA, 21 U.S.C. § 381 would
likely block reimportation.
But for the sake of argument, if we assume that the product is manufactured at an FDA-approved global facility (thereby, Sections 505 and 801 of
the FDCA do not present regulatory barriers), regulation alone will not prevent the newfound arbitrage problem of international patent exhaustion. And
given that a significant number of drugs prescribed in the U.S. are manufactured in India (1/3 of all generics, which make up 90% of the medicines prescribed), it is reasonable to assume that these facilities like at Dr. Reddy’s Labs
are FDA-approved.73 Thus, without regulatory obstacles overcoming the problems resulting from international exhaustion, pharmaceutical players will have
to creatively indicate in contracts to which countries the generic players are
authorized to sell the cheaper version of the product.

C. Creative Contracting to Avoid Arbitrage Effects
As Gilead has done with the various Indian generic companies, branded
pharmaceutical players can explicitly limit the ability of generic players to sell
in certain countries, like the U.S.. For example, a branded innovator company
72
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like Pfizer could choose to license Dr. Reddy’s in India on the condition that
it only sell the product in India, or maybe India and China. Thus, any subsequent sale into the U.S. (or to any country other than India and China) would
be considered unauthorized and thereby not fall under the exhaustion doctrine.
But what if the initial sale from a generic company to a domestic intermediary
in India is authorized, and then a subsequent sale to the U.S. occurs? In these
cases, where the licensee lacks privity with the end user, it is unclear how the
exhaustion doctrine would play out.
Nonetheless, if pharmaceutical companies are explicit enough in their
contracting terms, they could force the generic players to indemnify them
for any product diversion back into the U.S. market. By this standard, both
international manufacturers and downstream distributors would be liable for
any breach of contract. Therefore, given the change in exhaustion law and
the inability of pharmaceutical players to restrict entry on grounds of patent
infringement, the innovator companies may be able to sue on breach of contract grounds, though this may be more complicated given privity issues. And
if contractual territorial export restrictions are unsuccessful, there is one final
possibility – to create products that simply could not be imported back into the
U.S. given FDA approval restrictions.

D. Reducing Product Standards for the Indian Market
As noted above, finding generic players who manufacture drugs in unapproved facilities could be a simple fix to the reimportation issue given Section
801(d) of the FDCA. But due to the plethora of Indian-manufactured generics
in the U.S., this may not be a reasonable approach. An alternative – beyond
raising prices, voluntary licensing, and creative contracting—would be to sell
products in India that simply cannot be resold to the U.S. given FDA approval
restrictions, in particular, that are blocked by Section 505 of the FDCA.
To be specific, while U.S. pharmacos may not be able to control how
licensed products are manufactured or whether they will have a “not made
in an FDA-approved facility” stamp, they could sell lower quality drugs that
would not be approved at home. This would certainly raise ethical issues,
and may even result in reputational damage, but might be the only way out
of the patent dilemma caused by Lexmark’s international exhaustion if unique
contracting approaches fail. This begs the question: would the Indian FDAequivalent even accept such products?
In the case of remdesivir, India’s Drug Controller issued ‘emergency
use authorization’ to Gilead’s Voluntary Licensees only after U.S. FDA
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authorization had been granted to Gilead in the U.S., and after Japan’s drug
controller and Europe’s drug controller followed suit. Further, DCGI only
granted marketing approval to the Indian Voluntary Licensees of remdesivir
after laboratory and science-based testing and confirmation by India’s regulator
that the purity and quality of the remdesivir being manufactured in India by
the Voluntary Licensees is equivalent to the innovator’s original product.
While safety and manufacturing standards may sometimes be less stringent
in India relative to the US for pharmaceutical products, voluntary licensing
can actually up the ante in terms of ensuring equivalent quality and, in doing
so, mitigates the possibility of arbitrage from exhaustion by effectively forcing a “not FDA approved” stamp on the drug which raises consumer protection
issues from the Indian standpoint as well.

E. Indian Consumer Protection Act 2019
The Central Drugs Standard Control Organization (“CDSCO”) within the
Indian government is analogous to the US FDA, as defined by the Drugs and
Cosmetics Act 1940.74 In particular, the Drugs Controller General of Indian
(“DCGI”) within CDSCO approves drugs and sets manufacturing, sales,
import, and distribution standards within the country. Importantly, India’s 2019
Consumer Protection Act (“CPA”), repealing and replacing the 1986 version of
the Act, has the effect of expanding existing regulatory/consumer protection
law that outlines medical product liability.75
The Act allows for consumers to institute class action suits before a consumer-centric forum, with remedies ranging from money damages to compensate the consumer for any injury suffered due to manufacturer negligence
or fraud (including punitive damages) in addition to a full refund, as well as
injunctive relief to remove defects from the goods or withdraw the hazardous goods entirely from the market.76 Importantly, such expansive consumer
protections move India away from the stereotypical image of a country lacking critical regulatory oversight. Assuming the provisions of the Act are adequately enforced, pharmaceutical companies will not be able to play the game
of simply producing lower quality drugs for the Indian market to avoid parallel
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importation. Not only is this ostensibly unethical, but the CDSCO may also
have a newfound mandate through the CPA to limit such approvals.
IV. CONCLUSION

To conclude, this puts US pharmaceutical companies in a tough spot. While
Lexmark could have beneficial effects on drug prices in the US, as witnessed
by the various Bernie Sanders’ proposals, the impact in international markets like India is yet to be seen. Though pharmaceutical players could try to
increase foreign prices to reduce arbitrage opportunities resulting from reimportation, there is a risk of compulsory licensing. Voluntary licensing, especially when combined with creative contracting terms, could present a solution.
This is especially the case if there are contractual limitations as to which geographies the Voluntary License applies.
Without such contractual fine-tuning, licensing to well-established Indian
generics with FDA-approved facilities could allow them to circumvent FDA
import law, Section 801. Therefore, Lexmark has the effect of shifting burdens
from patent infringement lawsuits to rest on breach of contract cases. Finally,
PharmaCos could take the approach of lowering drug quality standards altogether in foreign countries like India, such that reimportation to the US would
be decisively restricted by the FDA’s Section 505. But with strengthened regulation in global markets – such as through the Indian Consumer Protection
Act 2019—it remains to be seen whether such a strategy would hold up. Thus,
regardless of the approach taken, it is clear that US drug manufacturers will
need to adjust their distribution strategy in developing countries like India due
to Lexmark’s international patent exhaustion on sale.

